Search
Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development
CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead...
Feb 21
With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space
Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as...
Feb 20
Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome
He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's...
Feb 18
The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy
Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations...
Feb 18
Biotech CEO Sisterhood: Serial entrepreneur Sheila Mikhail on overcoming obstacles and getting the job done, including multiple major acquisitions in her own career
Interviewed by ReCode Therapeutics' CEO Shehnaaz Suliman, she describes the journey of co-founding companies including AskBio, Bamboo...
Feb 18
Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success
She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory...
Feb 13
Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor
Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.
Feb 13
Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year
Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how...
Feb 11
John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics
He gives an optimistic take on the sector, describes why he thinks policy reforms can be positive but should be done strategically and...
Feb 11
Mizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he covers
He discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven
Feb 11
BioVenture VoiCes Episode 12: Flagship Pioneering's Avak Kahvejian
A General Partner at Flagship Pioneering, Avak describes his upbringing and studies in the Middle East and Montreal, Canada, working in...
Feb 10
Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.
Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was peronalized to dozens of the patient's neoantigens in this this ad
Feb 6
One Canal by Breakthrough - Ready for immediate occupancy in Cambridge, MA
Biotech companies looking for office and lab space in the heart of Cambridge, look no further. One Canal by Breakthrough , on First...
Feb 4
Biotech CEO Sisterhood: Avidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate culture
Interviewed by Sisterhood editorial board member Sheila Gujrathi, Sarah Boyce describes how to recognize dysfunction and the importance...
Feb 4
Cambridge, UK based LoQus23 Therapeutics will use a small molecule allosteric inhibitor of MutSβ to treat Huntington's
Co-Founder and CEO David Reynolds describes why LoQus23 is taking a small molecule approach to neurodegenerative diseases and why they...
Jan 29
Cambridge, UK based Harness Therapeutics, which topped up its seed financing this week, aims to use its oligo platform to treat Huntington's by upregulating the FAN1 nuclease across the brain
CEO Jan Thirkettle describes the company's approach to upregulating genes for neurodegenerative diseases and how Harness is out front in...
Jan 29
Akero's CEO comments on today's 96 week MASH data and the future of efruxifermin
Andrew Cheng describes the F4 patient population, and dicusses the efficacy and safety data Akero saw today. Plus, ongoing trials and how...
Jan 27
BioVenture VoiCes Episode 11: Pillar VC's Tony Kulesa
A Partner at Pillar VC, Tony describes his start at MIT, founding the MIT BioMakerspace, his work at Petri, being an early supporter of...
Jan 27
The co-founder of the Scientific Citizenship Initiative discusses the importance of scientific communication, and trying to place STEM PhDs into the Mass. State House as full-time policy advisors
In a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel...
Jan 22
IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C
President and CEO Professor Mallory Factor KCNG describes the mechanism of the therapy and the company's commercial launch and hiring....
Jan 22
.png){kind=logo}
